View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Belgyógyászati Intézet Anyagcsere Betegségek Tanszék Debrecen Nagyerdei krt. 98. 4032
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Évtizedek óta ismert, hogy a lipoprotein(a) összefüggésbe hozható a cardiovascularis betegségek fokozott előfordulásával, azonban csak az utóbbi évek kutatásai alapján kezdjük megismerni a fiziológiás és az érrendszeri betegségek kialakulásában játszott szerepét. A szerzők részletesen foglalkoznak a lipoprotein(a) fiziológiás szerepével, a magas lipoprotein(a)-szint okaival, annak csökkentési lehetőségeivel, illetve a lipoprotein(a) és a cardiovascularis betegségek közötti kapcsolattal. Orv. Hetil., 2014, 155(16), 607–614.

  • Tsimikas, S., Hall, J. L.: Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol., 2012, 60(8), 716–721.

  • Nordestgaard, B. G., Chapman, M. J., Ray, K., et al.: Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J., 2010, 31(23), 2844–2853.

  • Hoover-Plow, J., Huang, M.: Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism, 2013, 62(4), 479–491.

  • Rader, D. J., Cain, W., Ikewaki, K., et al.: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J. Clin. Invest., 1994, 93(6), 2758–2763.

  • Taleb, A., Witztum, J. L., Tsimikas, S.: Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark. Med., 2011, 5(5), 673–694.

  • Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., et al.: Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J. Am. Coll. Cardiol., 2012, 60(8), 722–729.

  • Bdeir, K., Cane, W., Canziani, G., et al.: Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood, 1999, 94(6), 2007–2019.

  • Boonmark, N. W., Lou, X. J., Yang, Z. J., et al.: Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J. Clin. Invest., 1997, 100(3), 558–564.

  • Berglund, L., Ramakrishnan, R.: Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol., 2004, 24(12), 2219–2226.

  • Dumitrescu, L., Glenn, K., Brown-Gentry, K., et al.: Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey. PLoS One, 2011, 6(1), e16604.

  • Cai, A., Li, L., Zhang, Y., et al.: Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Dis. Markers, 2013, 35(5), 551–559.

  • Kamstrup, P. R., Tybjaerg-Hansen, A., Steffensen, R., et al.: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA, 2009, 301(22), 2331–2339.

  • Li, Y., Luke, M. M., Shiffman, D., et al.: Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ. Cardiovasc. Genet., 2011, 4(5), 565–573.

  • Valenti, K., Aveynier, E., Leauté, S., et al.: Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians. Atherosclerosis, 1999, 147(1), 17–24.

  • Trommsdorff, M., Köchl, S., Lingenhel, A., et al.: A pentanucleotide repeat polymorphism in the 5’ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J. Clin. Invest., 1995, 96(1), 150–157.

  • Holmer, S. R., Hengstenberg, C., Kraft, H. G., et al.: Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation, 2003, 107(5), 696–701.

  • Luke, M. M., Kane, J. P., Liu, D. M., et al.: A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2007, 27(9), 2030–2036.

  • Chasman, D. I., Shiffman, D., Zee, R. Y., et al.: Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis, 2009, 203(2), 371–376.

  • Kathiresan, S., Willer, C. J., Peloso, G. M., et al.: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet., 2009, 41(1), 56–65.

  • Clarke, R., Peden, J. F., Hopewell, J. C., et al.: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med., 2009, 361(26), 2518–2528.

  • Røsby, O., Berg, K.: LPA gene: interaction between the apolipoprotein(a) size (‘kringle IV’ repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. J. Intern. Med., 2000, 247(1), 139–152.

  • Ober, C., Nord, A. S., Thompson, E. E., et al.: Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J. Lipid Res., 2009, 50(5), 798–806.

  • Gaeta, G., Lanero, S., Barra, S., et al.: Sex hormones and lipoprotein(a) concentration. Expert Opin. Investig. Drugs, 2011, 20(2), 221–238.

  • Berthold, H. K., Gouni-Berthold, I.: Hyperlipoproteinemia(a): clinical significance and treatment options. Atheroscler. Suppl., 2013, 14(1), 1–5.

  • Chennamsetty, I., Claudel, T., Kostner, K. M., et al.: FGF19 signaling cascade suppresses APOA gene expression. Arterioscler. Thromb. Vasc. Biol., 2012, 32(5), 1220–1227.

  • Frischmann, M. E., Kronenberg, F., Trenkwalder, E., et al.: In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int., 2007, 71(10), 1036–1043.

  • Karádi, I., Romics, L., Pálos, G., et al.: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin. Chem., 1989, 35(10), 2121–2123.

  • Kostner, K. M., März, W., Kostner, G. M.: When should we measure lipoprotein (a)? Eur. Heart J., 2013, 34(42), 3268–3276.

  • Tsimikas, S., Mallat, Z., Talmud, P. J., et al.: Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol., 2010, 56(12), 946–955.

  • Virani, S. S., Brautbar, A., Davis, B. C., et al.: Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2012, 125(2), 241–249.

  • Erqou, S., Kaptoge, S., Perry, P. L., et al.: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009, 302(4), 412–423.

  • Balogh, Z., Paragh, G.: The clinical significance of lipoprotein (a). [A liporptoein(a) klinikai jelentősége.] Orvosképzés, 1995, 70(5), 263–269. [Hungarian]

  • Gurdasani, D., Sjouke, B., Tsimikas, S., et al.: Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler. Thromb. Vasc. Biol., 2012, 32(12), 3058–3065.

  • Berg, K., Dahlén, G., Christophersen, B., et al.: Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet., 1997, 52(5), 254–261.

  • Jaeger, B. R., Richter, Y., Nagel, D., et al.: Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc. Med., 2009, 6(3), 229–239.

  • Kamstrup, P. R., Tybjaerg-Hansen, A., Nordestgaard, B. G.: Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler. Thromb. Vasc. Biol., 2012, 32(7), 1732–1741.

  • Thompson, G. R., Maher, V. M., Matthews, S., et al.: Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet, 1995, 345(8953), 811–816.

  • Kroon, A. A., Aengevaeren, W. R., van der Werf, T., et al.: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation, 1996, 93(10), 1826–1835.

  • Spence, J. D., Koschinsky, M.: Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler. Thromb. Vasc. Biol., 2012, 32(7), 1550–1551.

  • Leebmann, J., Roeseler, E., Julius, U., et al.: Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study. Circulation, 2013, 128(24), 2567–2576.

  • Stefanutti, C., D’Alessandri, G., Russi, G., et al.: Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atheroscler. Suppl., 2009, 10(5), 89–94.

  • Toth, P. P.: Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia. J. Clin. Lipidol., 2013, 7(3 Suppl), S6–S10.

  • Norata, G. D., Ballantyne, C. M., Catapano, A. L.: New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur. Heart J., 2013, 34(24), 1783–1789.

  • Cannon, C. P., Shah, S., Dansky, H. M., et al.: Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med., 2010, 363(25), 2406–2415.

  • Lippi, G., Favaloro, E. J.: Antisense therapy in the treatment of hypercholesterolemia. Eur. J. Intern. Med., 2011, 22(6), 541–546.

  • Berthold, H. K., Laudes, M., Krone, W., et al.: Association between the interleukin-6 promoter polymorphism –174G/C and serum lipoprotein(a) concentrations in humans. PLoS One, 2011, 6(9), e24719.

  • Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., et al.: Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med., 2010, 362(10), 906–916.

  • Schultz, O., Oberhauser, F., Saech, J, et al.: Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One, 2010, 5(12), e14328.

  • Krishna, R., Garg, A., Jin, B., et al.: Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol., 2009, 67(5), 520–526.